Literature DB >> 2877539

Development of tolerance to glyceryl trinitrate in an isolated human peripheral vein and its relation to cyclic GMP metabolism.

J Ahlner, R G Andersson, K L Axelsson, U Dahlström, E L Rydell.   

Abstract

Human peripheral vein (v. saphena magna) was exposed in vitro to glyceryl trinitrate (GTN) 0.1 mM for 1 h. The subsequent relaxant effect of GTN (10nM-0.1 mM) on vessels contracted by serotonin (0.25 microM) was significantly reduced on vessels preexposed to GTN as compared to control vessels, indicating a development of partial tolerance as far as the vascular smooth muscle relaxant effect is concerned. The impaired relaxant effect was paralleled by a reduced increment of intracellular cyclic GMP. This is, in turn, probably a consequence of both a diminished guanylate cyclase activity and an elevated phosphodiesterase activity in the GTN-tolerant vessels. The relaxant activity as well as the level of intracellular cyclic GMP were restored in GTN-tolerant vessels by dipyridamole (5 microM), an agent with phosphodiesterase inhibiting properties.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877539     DOI: 10.1111/j.1600-0773.1986.tb00143.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  4 in total

Review 1.  Mechanisms of action of nitrates.

Authors:  K E Torfgård; J Ahlner
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

Review 2.  Pharmacology of endothelium-derived nitric oxide and nitrovasodilators.

Authors:  L J Ignarro; G Ross; J Tillisch
Journal:  West J Med       Date:  1991-01

Review 3.  Interdependence of pharmacologically-induced and endothelium-mediated coronary vasodilation in antianginal therapy.

Authors:  E Bassenge; D J Stewart
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

4.  Effect of nitrate tolerance and dipyridamole on the response to SIN1 in the human isolated saphenous vein.

Authors:  M Bohyn; G Berkenboom; J Fontaine
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.